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Abstract cDNA encoding a novel putative G-protein-coupled 
receptor, named LyGPR (lymphocyte derived G-protein-coupled 
receptor) was cloned using a reverse transcription-PCR 
approach. The LyGPR amino acid sequence is 375 residues long 
and shows similarity (about 30-35% identity) both to the 
angiotensin receptors and members of the chemokine receptor 
family. Northern blot analysis revealed a 3.1-kb LyGPR 
transcript expressed predominantly in lung, heart and lymphoid 
tissues. LyGPR expression was also detected in the pre-B acute 
lymphoblastoid leukemia cell lines Reh and Nalm-6, in the 
Burkitt's lymphoma line Daudi, and in hematopoietic progenitor 
cells from bone marrow, as well as in B cells, T cells and 
monocytes from peripheral blood. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
G-protein-coupled receptors (GPRs) are integral membrane 
proteins responding to a wide range of extracellular signals 
including neurotransmitters, hormones, chemokines and reg-
ulatory peptides [1]. Stimulation of these receptors mediates 
activation of GTP-binding proteins (G-proteins), which regu-
late various cellular effectors, like specific enzymes and ion 
channels [2]. Molecular cloning of G P R genes has revealed 
a superfamily of structurally related proteins containing an 
extracellular N-terminus and seven hydrophobic membrane-
spanning oc-helices [3]. Novel members of this expanding fam-
ily are frequently isolated by use of PCR strategies or homol-
ogy cloning. 
The identification of receptors for IL-8 and some of the 
chemoattractants has led to an increased understanding of 
the role of G P R s in the biology of granulocytes and mono-
cytes. In lymphocytes, however, G P R s have so far gained less 
attention. Lymphocytes are known to express, often at low 
levels, receptors for various neuropeptides and opioid peptides 
playing roles in immune modulat ion (neuroimmunomodula-
tion). They also express several chemokines and chemokine 
receptors involved in lymphocyte adhesion and migration 
[4]. Recent findings have demonstrated important roles for 
chemokines in the regulation of growth and differentiation 
of lymphocytes [5,6], and this will hopefully accelerate the 
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identification of ligands to some of the novel chemokine or-
phan receptors showing predominant expression in lymphoid 
tissue. 
In this paper we report the isolation of a c D N A sequence 
encoding LyGPR, a novel putative GPR-coupled receptor ex-
pressed at highest levels in lung, heart and lymphocyte-en-
riched tissues. 
2. Materials and methods 
2.1. Isolation of LyGPR cDNA 
Degenerate oligonucleotide primers corresponding to conserved 
amino acid motifs NLA(V/L)AD in the second and (C/F)W(S/L)PY 
in the sixth transmembrane (TM) segment of G-protein-coupled re-
ceptors were constructed and used in PCR to amplify cDNA from the 
human B-cell line Daudi. The primer sequences, which include flank-
ing restriction enzyme sites, were: 5'-GGAATTCAA(C/T)CT(C/ 
G)GC(C/G)(C/G)T(C/G)GC(A/C/G/T)GA(C/T) (forward) and 5'-
GCTCTAGAT(C/G)(A/G)TA(A/C/G/T)GG(C/G)(A/G)(A/G)CCAG-
(A/C)A (reverse). cDNA was made as follows: Poly(A)+ RNA was 
isolated from about 1X106 Daudi cells using 300 ug Dynabeads 
oligo(dT)25 (Dynal, Norway) essentially as described by the manufac-
turer. However, instead of being eluted, the purified mRNA was kept 
annealed to the beads and was washed twice in RT buffer (50 mM 
Tris-HCl, pH 8.3, 75 mM KC1 and 3 mM MgCl2). A first-strand 
cDNA synthesis reaction (30 ul) was then performed directly in RT 
buffer containing 10 mM DTT, 0.5 mM dNTP, 15 U RNasin (Pro-
mega) and 200 U Superscript II (BRL) for 1 h at 42°C, 10 min at 
46°C and 10 min at 50°C, keeping the beads in suspension. After 
removal of the RT mix, the beads were washed once in TE (pH 
8.0) [7] and incubated for 5 min with 0.2 M NaOH, then washed 
once in SSPE [7] containing 0.1% Tween 20, and finally stored in 
100 ul TE at 4°C. 1 ul was used as template in a 25 ul PCR reaction 
containing Taq polymerase and buffer from Boehringer Mannheim, 
0.2 mM dNTP, and 10 pmol of each primer. Thirty-five cycles (94°C 
for 1 min, 55°C for 1 min, and 72°C for 1 min) of PCR were carried 
out. PCR products were cloned in pUC19 [7] and sequenced using 
Sequenase (Amersham) and the manufacturer's protocols. A 550-bp 
fragment showing similarity to GPR sequences was 32P-labelled by 
random priming and used as probe in library screening: about 
5X 105 pfu of a Xgtll cDNA library prepared from human fetal liver 
(Clontech) was screened using the manufacturer's protocols. 
2.2. Northern blot analysis 
Cell lines used were: the pro-B cell line Tom 1 [8]; the pre-B cell 
lines Reh (CRL 8286; ATCC) and Nalm-6 (ACC 128; DSM); the 
Burkitt's lymphoma cell line Daudi (CCL 213; ATCC); the T cell line 
Jurkat (TIB 152; ATCC), the myeloblastoid cell line KG-la (CCL 
246.1; ATCC) and the early erythroid cell line K562 (CCL 243; 
ATCC). The cells were grown in RPMI 1640 with 10% fetal bovine 
serum at 37°C. Poly(A)+ RNA was isolated from about 15X106 
cultured cells using oligo(dT)25 magnetic beads (Dynal, Norway). Fol-
lowing electrophoresis in a 1.2% agarose/formaldehyde gel, the RNA 
was blotted onto a Hybond-N membrane (Amersham) and subjected 
to hybridization with 32P-labelled DNA [7], 
2.3. RT-PCR expression analysis 
Normal lymphocytes, granulocytes and monocytes were all isolated 
from buffy coats of normal donors. B cells were isolated by use of 
Dynabeads-M450 CD19 (Dynal, Norway) as previously described 
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Fig. 1. Sequence alignment of LyGPR with related G-protein-coupled receptors. Multiple amino acid sequence alignment (ClustalW 1.6) [14] of 
LyGPR with the angiotensin II receptor 1A, AT.1A (SwissProt P30556); the orphan chemokine receptor BLR1 (P32302), the low-affinity IL-8 
receptor IL8.RB (P25025) and the orphan chemokine receptor V28 (P49238). Amino acids identical or similar in at least two of the sequences 
are indicated by black or shaded areas, respectively. Potential sites for ^-linked glycosylation in LyGPR are marked by inverted triangles. Pu-
tative transmembrane regions in LyGPR predicted by the program TMpred (ISREC) are indicated by dotted lines above the sequences. The 
solid lines below the sequences show the putative transmembrane regions in IL8.RB (information obtained from SwissProt). The cDNA se-
quence of LyGPR is deposited in the EMBL Nucleotide Sequence Database and has the accession number X98510. 
[9,10], granulocytes and monocytes by use of Dynabeads-M450 CD15 
and CD14, respectively, following the same procedure as for B cells, 
except that beads were removed after cell lysis. T cells were isolated by 
depletion of HLA class II expressing cells using Dynabeads-M450 pan 
human HLA class II. 
Hematopoietic progenitor cells were isolated from human bone 
marrow obtained by iliac crest aspiration from adult volunteers. 
Mononuclear cells were isolated by Ficoll-Hypaque gradient centrifu-
gation (Lymphoprep; Nycomed, Norway), and CD34+ cells and 
CD19+ cells were obtained from these by positive selection using 
immunomagnetic beads [11]. Subpopulations of CD34+ cells and 
CD19+ cells were isolated by flow cytometric cell sorting (FACStar 
Plus cell sorter; Becton Dickinson). CD34+CD38~ cells were ob-
tained after costaining with phycoerythrin (PE)-conjugated anti-
CD34 (HPCA-2, Becton Dickinson, San Jose, CA, USA) and fluo-
rescein isothiocyanate (FITC)-conjugated anti-CD38 (IOB6, Immuno-
tech, Marseilles, France). Mature bone marrow B cells (CD19+IgM+) 
and pro- and pre-B cells (CD19+IgM~) were obtained after staining 
with PE anti-CD19 (HD37; DAKO, Denmark) and FITC anti-IgM 
(DAKO, Denmark). 
Poly(A)+ RNA was isolated from about 3x 105 cells using 100 u.g 
oligo (dT)25 beads. The RNA was eluted in 10 ul H20. First strand 
cDNA was made from 5 ul in a 15 ul RT reaction using Superscript II 
(BRL) and similar conditions as described previously, except that now 
the cDNA was in solution. A mock reaction without transcriptase was 
performed on the rest of the mRNA and used as control in subse-
quent PCR experiments to check for contaminating genomic DNA. 
For detection of LyGPR transcripts 1 ul of the cDNA was ampli-
fied in a 25 ul PCR (40 cycles: 94°C for 1 min, 58°C for 1 min, 72°C 
for 1 min) with primers LyGPR.forw. (5'- GCACGAGCGGTAC-
TACGAC) and LyGPR.rev. (5'- GACATCCGCGAAACAGAAG). 
These primers specify a 277-bp fragment located in the protein-coding 
part (between TM II and TM V) of the transcript. 
Primers for ß-actin were: 5'-GTGAATTCCTTCTACAATGAGC-
TGCGTG (forward) and 5'-CGTCTAGAGCCATCTCTTGCTC-
GAAGTC (reverse) (located at nt 307 and nt 705, respectively, in 
sequence X00351 [12]. PCR was performed as for LyGPR, except 
that only 35 cycles were run, and the amount of template was reduced 
to 0.1 itl. 
3. Results and discussion 
A PCR approach based on degenerate primers correspond-
ing to TM II and TM VI sequences common to GPRs was 
used in order to identify novel GPR genes expressed in B cells. 
Amplification of Daudi cDNA, as described, resulted in prod-
ucts appearing as one major band of about 550 bp when 
analyzed by agarose gel electrophoresis. After cloning and 
sequencing, one of the cDNAs showing characteristics of 
GPR sequences was chosen for further characterization. To 
obtain full-length cDNA, a À.gtl 1 cDNA library from human 
fetal liver was screened using the 550-bp fragment as probe. A 
positive clone containing a 2.4-kb insert was sequenced. This 
cDNA has a 1125-bp open reading frame flanked by 770-bp 
5'- and 510-bp 3'-sequences. The deduced amino acid se-
quence is 375 residues long and specifies a putative GPR, 
designated LyGPR (lymphocyte derived G-grotein-coupled 
receptor. It has three potential N-glycosylation sites (Asn-25, 
-32 and -44) located in the N-terminal end, and is predicted by 
hydrophobicity analysis [13] and the computer program 
TMpred (ISREC) to contain seven transmembrane segments 
(Fig. 1). 
The sequence shows some similarity to both angiotensin 
and chemokine receptor sequences (Fig. 1). It is 32% and 
35% identical to the angiotensin II receptor ATI A [15] and 
IL-8 receptor B [16], and 33 and 35% identical to the orphan 
chemokine receptors BLR1 [17] and V28 [18], respectively. 
The sequence motif DRY, located at the end of TM III, is 
conserved in many GPRs and has been shown to be impor-
tant for G-protein-mediated signalling [19]. In chemokine re-
ceptors an extended motif, DRYLAIV, is particularly con-
served. LyGPR lacks this motif, as well as a conserved 
cysteine residue, which is located close to TM I in the N-
terminal end of most chemokine receptors. Thus, LyGPR 
seems to be only distantly related to the typical chemokine 
receptors, and it is presently unclear whether its putative li-
gand is a chemokine or perhaps a neuropeptide. A recent 
report describes the sequence of a protein which is identical 
to LyGPR, and is encoded by a gene localized to chromosome 
7p22 [20]. When a panel of chemokines was tested on trans-
fected cells expressing this protein, no response could be de-
tected [20]. 
Northern blot analysis of LyGPR expression in various 
human tissues (Fig. 2A,B) reveals a single, 3.1-kb transcript, 
which is most abundant in lung, heart and lymphoid tissues. 




Fig. 2. Expression of LyGPR in human tissues and cells. Tissue distribution of LyGPR mRNA (A) in tissues important in the immune system 
and (B) in various tissues. Northern blots containing 2 ug poly(A)+ RNA per lane were obtained from Clontech (Palo Alto, CA, USA) and 
hybridized using a labelled 550-bp LyGPR cDNA fragment (PBL: peripheral blood leukocytes). C: LyGPR expression in hematopoietic cell 
lines. The Northern blot contains approximately 3 ug poly(A)+ RNA per lane. RT-PCR analysis of LyGPR expression in purified hemato-
poietic cells from (D) bone marrow and (E) peripheral blood. Amplification of ß-actin was performed with fewer cycles and less template (1/ 
10) than the amplification of LyGPR. The DNA was stained with SYBR Green I (Molecular Probes, Inc.). 
Within the immune tissues tested, LyGPR mRNA is readily 
detected in spleen, lymph node and appendix (adult tissue), 
and a relatively high level of LyGPR expression in seen in 
fetal liver (Fig. 2A). When mRNA from cultured cells repre-
senting various hematopoietic linages was analyzed, LyGPR 
expression was found in the pre-B cell lines Reh and Nalm-6 
and in the mature B cell line Daudi (Fig. 2C). In Nalm-6 and 
Daudi minor transcripts of 3.8 and ~ 8 kb are detectable in 
addition to the predominant 3.1-kb transcript. No LyGPR 
mRNA was detected in the pro-B cell line Tom 1, the early 
T cell line Jurkat, the myeloblast cell line KG-la or in the 
early erythroid cell line K562 (Fig. 2C). Except from a 0.7-kb 
difference in estimated transcript size, these expression data 
are largely in line with what is reported by Owman et al. [20], 
who in addition demonstrated ubiquitous expression within 
the central nervous system. 
The expression pattern of LyGPR in purified cell popula-
tions from bone marrow (Fig. 2D) and peripheral blood (Fig. 
2E) was examined using RT-PCR. With this sensitive techni-
que LyGPR mRNA could not be detected in the most imma-
ture hematopoietic cells (CD34+CD38-), but was found in 
CD34+CD38+ cells. This population contains most hemato-
poietic precursor cells capable of in vitro colony formation, 
including cells with multilineage potential. Among bone mar-
row B lineage cells LyGPR mRNA was found in 
CD19+IgM~ cells, the population containing pro- and pre-B 
cells. In the experiment presented in Fig. 2E, no LyGPR tran-
scripts are detectable in mature, IgM+ B cells from bone 
marrow. This result is, however, not consistent, as LyGPR 
expression in CD19+IgM+ cells has sometimes been observed. 
In peripheral blood B cells LyGPR mRNA is readily detected 
by RT-PCR analysis (Fig. 2E). We were, like Owman et al. 
[20], unable to detect LyGPR transcripts in purified peripheral 
blood B cells by Northern blot analysis (data not shown), 
indicating a relatively weak expression of LyGPR in resting 
B lymphocytes. Circulating T cells and CD14+ monocytes 
also show expression of LyGPR, albeit at a lower level than 
B cells, whereas no LyGPR mRNA was detected in CD 15+ 
cells (neutrophils and eosinophils) (Fig. 2E). In hematopoietic 
cells the pattern of LyGPR expression shows some similarity 
62 A.M. Kvingedal, E.B. SmelandlFEBS Letters 407 (1997) 59-62 
to that of BLR1, an orphan receptor most abundantly ex-
pressed in B cells [17], but also present in peripheral T cells 
[21] and monocytes [22]. BLR1 is quite closely related to the 
chemokine receptors and is suggested to function in the reg-
ulation of lymphocyte traffic and in neuroimmune communi-
cation. In peripheral blood BLR1 defines mature, recirculat-
ing B cells and a subset of T-helper memory cells [21]. 
LyGPR is expressed at various stages of B cell differentia-
tion, including pro- and pre-B cells. The high level of LyGPR 
expression in the pre-B cell line Nalm-6 is intriguing. It is not 
due to gene amplification, indicated by Southern blot analysis 
of Nalm-6 genomic DNA (data not shown). Whether the 
variable expression of LyGPR in B cell lines and various 
lymphoid tissues reflects differences in activation and/or differ-
entiation stages during B cell development, remains to be 
clarified. However, we are currently in the process of generat-
ing LyGPR-specific monoclonal antibodies, which will be use-
ful for a more precise identification and phenotypic character-
ization of LyGPR expressing cells, and for the elucidation of 
the role of LyGPR in B cell development. 
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